2024
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Mohammad Aghaei A, Weleff J, Martins B, Ing K, Fontenele R, Barnett B, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. Current Addiction Reports 2024, 11: 685-712. DOI: 10.1007/s40429-024-00574-y.Peer-Reviewed Original ResearchTreatment of AUDUse disorderTreatment of alcohol use disordersModalities of psychotherapyAlcohol use disorderPsychedelic treatmentPsychotherapeutic interventionsTreat AUDPsychedelic compoundsPsychedelic trialsPsychotherapySmall numbers of participantsPsychedelicsMagnitude of improvementMethodological shortcomingsAUDNumbers of participantsClinical trialsDisordersReviewed trialsShort follow-up periodFollow-up periodTherapy methodsEmpirical evidenceNo significant differenceFrom taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff J, Nunes J, Costa G, Sofuoglu M, MacLean R, De Aquino J. From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024 PMID: 38627909, PMCID: PMC11480258, DOI: 10.1111/bcp.16045.Peer-Reviewed Original ResearchOpioid use disorderChronic painLong-term opioid therapyManagement of chronic painPain management alternativeOpioid-induced analgesiaInnovative treatment optionsManagement of painReverse painCentral sensitizationOpioid therapyPain controlTreatment optionsClinical challengeClinical trialsPainPotential therapeutic applicationsPain experiencePotential of psychedelicsNovel therapeuticsHuman evidenceOpioid crisisNeurobiological substratesOpioidExploration of novel therapeutics
2022
Black Pepper (Piper nigrum) for Tobacco Withdrawal: A Case Report
Weleff J, Dore S, Anand A, Barnett B. Black Pepper (Piper nigrum) for Tobacco Withdrawal: A Case Report. Case Reports In Psychiatry 2022, 2022: 5908769. PMID: 36530582, PMCID: PMC9757938, DOI: 10.1155/2022/5908769.Peer-Reviewed Original ResearchNicotine withdrawalTobacco withdrawalWithdrawal-associated anxietyTobacco use disorderTreating nicotine withdrawalNicotine cravingTobacco cigarettesUse disorderSensorimotor experienceEffective novel treatmentCravingMotor urgeSignificant public health concernSmall clinical trialsCorrectional settingsNonresearch settingsWithdrawalCase reportClinical trialsPublic health concernNovel treatmentCorrectional facilitiesPatient reportsTobacco cessationTobacco usePsychedelics in the Treatment of Substance Use Disorders
Barnett B, Weleff J. Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 2022, 52: 365-370. DOI: 10.3928/00485713-20220804-01.Peer-Reviewed Original ResearchSubstance use disordersPsychedelic experienceTreatment of substance use disordersLysergic acid diethylamideSubjective effectsUse disorderAcid diethylamidePlacebo-controlled trialPsychedelicsBehavioral changesTherapeutic potentialClinician concernsLife narrativesDisordersFacilitation programTreatment paradigmTherapeutic efficacyClinical trialsTreatment potentialObservational studyPsilocybinDiethylamideTrialsSubstancesOpioidThe State of the Catatonia Literature: Employing Bibliometric Analysis of Articles From 1965–2020 to Identify Current Research Gaps
Weleff J, Barnett B, Park D, Akiki T, Aftab A. The State of the Catatonia Literature: Employing Bibliometric Analysis of Articles From 1965–2020 to Identify Current Research Gaps. Journal Of The Academy Of Consultation-Liaison Psychiatry 2022, 64: 13-27. PMID: 35840002, DOI: 10.1016/j.jaclp.2022.07.002.Peer-Reviewed Original ResearchConceptsBibliometric analysisBibliometric analysis of articlesCoauthorship network analysisComprehensive bibliometric analysisWeb of Science Core CollectionProportion of articlesScience Core CollectionContent analysisProportion of neuroimaging studiesAcademy of Consultation-Liaison PsychiatryAnimal/in vitro studiesConsultation-liaison psychiatryGeneral medical conditionsCore collectionClinical trialsAnalysis of articlesCase reportMedical conditionsResearch gapMetadataCoauthorshipResearch articlesIncreasing case reportsStudy periodWeb
2021
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020
Barnett B, Parker S, Weleff J. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. International Journal Of Drug Policy 2021, 99: 103473. PMID: 34624734, DOI: 10.1016/j.drugpo.2021.103473.Peer-Reviewed Original ResearchConceptsNational Institutes of HealthNational Institutes of Health grantsPsychedelic-assisted therapyResearch funding bodiesClinical trialsPublic funder of biomedical researchMental health conditionsNational Institutes of Health fundingNational Institutes of Health RePORTERFunding bodiesUnited States National Institutes of HealthSchedule 1 drugFunder of biomedical researchInstitutes of HealthFunding clinical trialsNIH grant supportHealth conditionsPsychedelic renaissanceUnited KingdomGrant fundingGrant databasesStudy periodPublic funders